First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment ...

The advancement of artificial intelligence (AI) algorithms has opened new possibilities for the development of robots that ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...

First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to Reached written alignment with FDA on inclusion of =3 months of safety data from ASPIRE trial evaluating TSHA-102 (N=3 ...

This milestone marks significant progress in the first-in-human evaluation of AAVantgarde's dual-AAV gene therapy designed to address the underlying cause of vision loss in patients with USH1BLONDON a ...

The primary and mass education ministry has recently directed the NCTB to change the assessment and marks distribution system ...

Real-world adverse events are rarely monocausal. They emerge from the interaction of drug exposure, comorbid conditions, physiological states, concomitant medications, and patient-specific ...

Taysha Gene Therapies (TSHA) announced progress across the TSHA-102 pivotal program, an intrathecally delivered AAV9 gene therapy with disease ...

At the federal level, the U.S. Food and Drug Administration finally removed the “black box warning” on estrogen products, ...

Immunofoco, a clinical-stage biotechnology company advancing innovative CAR-T cell therapies for solid tumors, recently announced clinical data from its Phase I/IIa study of IMC002, a VHH-based ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN FRANCISCO, Calif, Jan. 07, ...

AudioEye reports that in 2026, digital accessibility is mandatory for all online organizations, highlighting key laws and ...